Sol-Gel Technologies (SLGL) Liabilities and Shareholders Equity (2016 - 2026)

Sol-Gel Technologies' (SLGL) quarterly Liabilities and Shareholders Equity came in at $58.6 million in Q1 2026, up 116.35% year-on-year from $27.1 million in Q1 2025, and up 95.71% on a QoQ basis from $29.9 million in Q4 2025.

Sol-Gel Technologies (SLGL) Liabilities and Shareholders Equity (2016 - 2026) Analysis & Trends

Sol-Gel Technologies (SLGL) has 11 years of Liabilities and Shareholders Equity data on file, last reported at $58.6 million in Q1 2026.

  • On a quarterly basis, Liabilities and Shareholders Equity rose 116.35% year-over-year to $58.6 million in Q1 2026; TTM through Mar 2026 was $162.4 million, a 9.79% increase from a year earlier, with the FY2025 full-year figure at $29.9 million, down 16.54% from the prior year.
  • Liabilities and Shareholders Equity for Q1 2026 stood at $58.6 million, up from $29.9 million in the prior quarter.
  • Over the last five years, Liabilities and Shareholders Equity for SLGL reached as high as $58.6 million in Q1 2026 and fell as low as $27.1 million in Q1 2025.
  • Historically, Liabilities and Shareholders Equity has averaged $44.6 million across 5 years, with a median of $45.3 million in 2023.
  • Across the five-year window, Liabilities and Shareholders Equity plunged 32.61% in 2022 and surged 116.35% in 2026, its largest moves.
  • Year by year, Liabilities and Shareholders Equity stood at $46.6 million in 2022, then dropped by 2.88% to $45.3 million in 2023, then retreated by 20.85% to $35.8 million in 2024, then slipped by 16.54% to $29.9 million in 2025, then soared by 95.71% to $58.6 million in 2026.
  • Per Business Quant data, the three most recent Liabilities and Shareholders Equity figures were $58.6 million in Q1 2026, $29.9 million in Q4 2025, and $34.6 million in Q3 2025.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Liabilities and Shareholders Equity (Qtr)
1 Oculis Holding AG 68,785.72 Bn 68,785.72 Bn - 311.58 Mn
2 Nanobiotix 1,895.57 Bn 1,895.51 Bn - 78.88 Mn
3 BeOne Medicines 471.35 Bn 466.56 Bn 1.35 Bn 8.55 Bn
4 NuCana 279.75 Bn 279.75 Bn - 39.68 Mn
5 Vertex Pharmaceuticals 120.24 Bn 113.00 Bn 2.59 Bn 26.48 Bn
6 Regeneron Pharmaceuticals 67.80 Bn 59.04 Bn 3.31 Bn 40.87 Bn
7 Belite Bio 62.51 Bn 62.51 Bn - 811.27 Mn
8 Argenx Se 57.38 Bn 57.38 Bn 1.41 Bn 10.03 Bn
9 Revolution Medicines 37.78 Bn 37.78 Bn - 2.25 Bn
10 Sol-Gel Technologies 227.58 Mn 217.44 Mn - 58.55 Mn

Historic Data

Download Data
DateValue
Mar 31, 2026 58.55 Mn
Dec 31, 2025 29.92 Mn
Sep 30, 2025 34.59 Mn
Jun 30, 2025 39.31 Mn
Mar 31, 2025 27.06 Mn
Dec 31, 2024 35.85 Mn
Sep 30, 2024 42.98 Mn
Jun 30, 2024 42.01 Mn
Mar 31, 2024 39.91 Mn
Dec 31, 2023 45.29 Mn
Sep 30, 2023 49.86 Mn
Jun 30, 2023 55.10 Mn
Mar 31, 2023 49.04 Mn
Dec 31, 2022 46.63 Mn
Sep 30, 2022 51.29 Mn
Jun 30, 2022 54.98 Mn
Mar 31, 2022 56.06 Mn
Dec 31, 2021 69.19 Mn
Sep 30, 2021 52.83 Mn
Jun 30, 2021 46.41 Mn